Route of administration: Oral
Sponsors
SK Biolabs, Sun Pharma Advanced Research Company Limited, ICMR New Delhi, Glenmark Pharmaceuticals Ltd, Ministry of AYUSH Govt of India
Conditions
Health Condition 1: C729- Malignant neoplasm of central nervous system, unspecifiedHealth Condition 1: D578- Other sickle-cell disordersHealth Condition 1: F988- Other specified behavioral and emotional disorders with onset usually occurring in childhood and adolescenceHealth Condition 1: K729- Hepatic failure, unspecifiedHealth Condition 1: L40- Psoriasis
Health Condition 2: M069- Rheumatoid arthritis, unspecifiedHealth Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified
Phase 1
A trial to test the safety of a drug.
Active, not recruitingCTRI/2017/11/010680
Target: 100Updated: 2021-11-24
A study to evaluate effect of single oral dose of SDN-118 Capsules in healthy adult Human subjects
Active, not recruitingCTRI/2020/03/024009
Target: 72Updated: 2021-11-24
A pharmacokinetic study of novel formulations of ISC 17536 in healthy male adults
Active, not recruitingCTRI/2020/09/028094
Target: 108Updated: 2021-11-24
Phase 2
Phase 3
Phase 4
Unknown Phase
A study of Temozolomide Powder For Oral Suspension in Cancer Patients
Active, not recruitingCTRI/2021/04/032776
Target: 14Updated: 2022-10-17
A Study of Methotrexate Tablets 2.5 mg in Adult Patients with Mild to Severe Psoriasis or Rheumatoid Arthritis
Active, not recruitingCTRI/2021/08/035480
Target: 48Updated: 2024-10-14
A clinical study to assess the drug exposure and evaluation of pretomanid, following oral administration in participants with liver disease compared with healthy subjects.
RecruitingCTRI/2025/03/082318
Target: 24Updated: 2026-02-02